# Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer

Source: https://onco.cc/trials/nct07188246/  
OnCo record `nct07188246` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab in triple-negative breast cancer, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, now recruiting.

## Summary

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer is a phase 2, interventional study registered as NCT07188246 by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, with a registry enrolment figure of 40 participants, started 2026-01-19 and due to reach its primary completion in 2027-07. Interventions recorded: Radiation; Pembrolizumab (KEYTRUDA®). Conditions listed: Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer Invasive; Breast Cancer Triple Negative. Triple-negative eligibility wording from the registry: "Stage IIA is eligible for triple negative and HER2+ breast cancers". Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: BRINK
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07188246
- Phase: 2
- Setting: A Trial of Neoadjuvant, Hypofractionated Radiation, With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy, in Stage 3 or High-risk Stage 2 Breast Cancer
- Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07188246: https://clinicaltrials.gov/study/NCT07188246

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07188246.json